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Alzheimer’s disease is neuropathologically characterized by the accumulation of amyloid-b protein into
senile plaques that are sites of chronic inﬂammation involving reactive microglia, astrocytes, and proin-
ﬂammatory molecules, such as interleukin-1b and tumor necrosis factor-a. The human CCAAT/enhancer-
binding protein (CEBP) delta (CEBPD) is known to be induced in many inﬂammation-related diseases. In
Alzheimer’s disease, this protein is responsive to amyloid-b and proinﬂammatory cytokines in astrocytes.
However, the functional role of CEBPD in astrocytes remains largely unclear. In this study, we show that
CEBPD is upregulated by interleukin-1b through the mitogen-activated protein kinase p38 (MAPKp38)
signaling pathway and phosphorylated by glycogen synthase kinase (GSK)-3b at Ser167 in astrocytes.
CEBPD in astrocytes is associated with microglia activation and migration in amyloid precursor protein
transgenic mice (AppTg) mice. We further identiﬁed that the monocyte chemotactic protein-1, a chemo-
attractive factor, and migration factors matrix metalloproteinase-1 and -3 are responsive to GSK3b-
mediated CEBPD Ser167 phosphorylation. Our results revealed the novel regulation of LiCl on astrocytes
and that GSK3b-mediated CEBPD phosphorylation in astrocytes plays an important role in the activation of
microglia.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease that
occurs predominantly in elderly people and leads to behavioral
changes. Two types of monocyte-macrophage cells, including
parenchymal microglial cells and blood-borne monocytes, have
been suggested to exist in brain tissue (Guillemin and Brew, 2004;s and Biosignal Transduction,
eng Kung University, Tainan
2083663.
Wang).
Inc. Open access under CC BY-NC-NDMinagar et al., 2002). Microglia/macrophages are the principal
immune cells in the central nervous system (CNS), are concomitant
with inﬂammatory brain disease, and play a signiﬁcant role in host
defense against invading micro-organisms. Astrocytes are primary
supportive cells in the CNS and are believed to play an essential role
in neuronal survival, function, and neurogenesis (Hazell, 2002;
Nedergaard, 1994; Pfrieger and Barres, 1997; Song et al., 2002).
Astrocytes generate a response to brain injury through the pro-
duction of growth factors that can further promote microglial
growth and activation or modulate their cytotoxic activity (Ji et al.,
1996; Riccio et al., 1999). Although microglia/macrophages and
astrocytes have been suggested to play a vital role in AD patho-
genesis, the regulation of the crosstalk between microglia and as-
trocytes have not been fully investigated.
Glycogen synthase kinase (GSK)-3 is a highly conserved serine/
threonine protein kinase and is ubiquitously expressed in all
eukaryotes. GSK3 acts as a downstream regulatory switch that license.
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G-proteinecoupled receptors; in addition, GSK3 is involved in
many processes, including cytoskeletal organization, cell cycle
regulation, proliferation, and apoptosis. Mammalian cells have a
and b GSK3 isoforms. GSK3b has been shown to favor previous
phosphorylation of its substrate before it phosphorylates the sub-
strate (Cohen and Frame, 2001). GSK3b plays an important role in
the regulation of synaptic plasticity, cell survival, and circadian
rhythms in the mature CNS. Although the activation of GSK3b was
observed in inﬂamed astrocytes (Beurel and Jope, 2009; Kim et al.,
2007), little is known about the details of GSK3b biology in astro-
cytes in neuroinﬂammatory conditions.
CCAAT/enhancer-binding protein (CEBP) delta (CEBPD) is a
member of the CCAAT/enhancer-binding protein (C/EBP) family and
servesas a transcription factor for tissuedifferentiation,metabolism,
and immune responses (Ishii et al., 2005; Lai et al., 2008; Ramji and
Foka, 2002; Takeji et al., 2004). CEBPD is expressed at relatively low
levels in physiological conditions and is upregulated by a variety of
extracellular stimuli, suchas interleukin (IL)-6 (SanfordandDeWille,
2005), lipopolysaccharide (Liu et al., 2003), IL-1b (Ko et al., 2012;
Svotelis et al., 2005), tumor necrosis factor (TNF)-a (Cardinaux
et al., 2000) and interferon-g (Tengku-Muhammad et al., 2000).
Moreover, CEBPD also can induce expressions of cytokines including
IL-6, IL-1b, and TNF-a (Akira et al., 1990; Kinoshita et al., 1992; Poli,
1998). In AD, phagocytic microglia travel to the site of injury in the
inﬂamed brain to engulf the offending material and secrete proin-
ﬂammatory factors that promote cell proliferation. Activated
phagocyticmicroglia also interactwith astrocytes and neural cells to
ﬁght off infections as quickly as possible with minimal damage to
healthy brain cells. Elevated CEBPD expression was observed in the
astrocytes of ADpatients (Li et al., 2004). A recent study showed that
astrocytic CEBPD responds to IL-1b and contributes in attenuating
macrophage-mediated phagocytosis of damaged neurons through
pentraxin-3 (Ko et al., 2012).
Posttranslational modiﬁcations play an important role in pre-
cisely controlling protein function. CEBPD is an acetyl- and sumo-
conjugated protein (Wang et al., 2006). We provided models to
illustrate that CEBPD can serve as a positive or negative regulator
through its various posttranslational modiﬁcations in transcrip-
tional regulation (Lai et al., 2008; Wang et al., 2006, 2008). In this
study, we demonstrated that MAPKp38 mediated IL-1beinduced
CEBPD gene expression and GSK3b modiﬁed CEBPD at Ser167.
Importantly, the conditioned medium harvested from astrocytes
expressing CEBPDS167A and LiCl-treated cells show similar atten-
uation of microglia/macrophages migration. We determined that
the phosphorylation of CEBPD at Ser167 participated in the tran-
scription of monocyte chemotactic protein-1 (MCP-1), matrix
metalloproteinase-1 (MMP-1), and matrix metalloproteinase-3
(MMP-3) genes is altered by a direct binding to their promoter re-
gions in astrocytes.
2. Methods
2.1. Materials
An anti-aetubulin antibody was purchased from Sigma (St
Louis, MO, USA). An anti-induction of brown adipocytes 1 (Iba1)
antibody was purchased from Wako (Osaka, Japan). Anti-CEBPD,
-glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and
-cyclooxygenase 1 (COX-1) antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phophoeGSK3a/b
(S21/S9) and anti-phosphoep38 were purchased from Cell
Signaling Technology (Danvers, MA, USA). Anti-phophoeCEBPD
S167 and T171 were produced by GeneTex (Irvine, CA, USA). The
TRIzol RNA extraction reagent, Lipofectamine 2000, Dulbeco’smodiﬁed Eagle’s medium (DMEM), SuperScript III, anti-glial ﬁbril-
lary acidic protein (GFAP) antibody, and Opti-MEM medium were
obtained from Invitrogen (Carlsbad, CA, USA). All oligonucleotides
were synthesized byMDBio Inc (Taipei, Taiwan). Fetal bovine serum
was purchased from HyClone Laboratories (Logan, UT, USA). Cebpd-
deﬁcient mice were obtained from Dr E. Sterneck (Sterneck et al.,
1998).
2.2. Cell culture
U373MG (human glioblastoma-astrocytoma cell line) cells were
cultured in DMEM, containing 10% fetal bovine serum, 100 mg/mL
streptomycin, and 100 U/mL penicillin. BV-2 cells (murine micro-
glial cell line, immortalized by infection with with v-raf/c-myc re-
combinant retrovirus) (Blasi et al., 1990) were grown in DMEMwith
5% fetal bovine serum, 100 mg/mL streptomycin, and 100 U/mL
penicillin. For inducible expression of CEBPD wild type and mu-
tants, the pMT/HA-CEBPD WT, pMT/HA-CEBPD S167A and pMT/
HA-CEBPD T171A constructs were introduced into U373MG cells
and stable clones were selected using G418.2.3. In vitro calf intestinal alkaline phosphatase assay
For in vitro dephosphorylation of CEBPD, the cell extracts were
combined with 10 U of alkaline phosphatase (New England Biolabs,
Beverly, MA, USA) containing 50 mM Tris (pH 7.9), 100 mM NaCl, 10
mMMgCl2, and 1 mM dithiothreitol (DTT) in calf intestinal alkaline
phosphatase buffer and then the mixturewas incubated at 37 C for
1 hour.2.4. In vitro kinase assay
For the in vitro phosphorylation analysis, the wild type His-tag-
gedeCEBPD and various point mutations of CEBPD were puriﬁed
from Escherichia coli BL21 (DE3). These CEBPD proteins and active
GSK3b or casein kinase I (CKI) were used to examine CEBPD phos-
phorylation in vitro. Each reaction (20 mL) contained 1 mg of puriﬁed
CEBPD, 0.015 U of active GSK3b or CKI, 2 mCi of [g-32P] adenosine
triphosphate (GE Healthcare) or 1 mM ATP (New England Biolabs)
and 2 mL of 10X kinase buffer containing 500 mM 4-(2-hydroxy-
ethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.4), 10 mM
MgCl2,1 mM ethylene glycol tetraacetic acid (EGTA), and 1mMDTT.
The phosphorylation reactions were incubated at 37 C for 15 mi-
nutes. After the incubation, half of the reactionwas added to 10 mL of
2Xelectrophoresis sample buffer,whichwas thenheated to95 C for
5 minutes. Proteins in the mixtures were immediately separated
using sodium dodecyl sulfate polyacrylamide gel electrophoresis.2.5. Plasmid transfection and reporter gene assay
Cells were replated 24 hours before transfection at an optimal
density in 2 mL of fresh culture medium in a 6-well plastic plate.
They were then transfected with plasmids using Lipofectamine
2000 according to the manufacturer’s instructions. The total
amount of DNA for each experiment was matched with the empty
vector. The Opti-MEM media were changed to conditional medium
and incubated for 15 hours. The promoter fragments of MCP-1
(approximately734 to 37),MMP1 (approximately600 to 71) and
MMP3 (approximately 600 to 65) were cloned using polymerase
chain reaction (PCR) of genomic DNA from HeLa cells and inserted
into the promoterless pGL2-Basic vector (Promega, Madison, WI).
After transfection, the luciferase activities in cell lysates were
measured using the luciferase assay system as per the manufac-
turer’s instructions (Promega).
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Total RNAwas isolated using the TRIzol RNA extraction kit and 1
mg of RNA was subjected to reverse transcription (RT)-PCR using
SuperScript III. Speciﬁc primers used for the RT-PCR analysis were:
for CEBPD, 50-AGCGCAACAACATCGCCGTG-30 and 50-GTCGGGTCT-
GAGGTATGGGTC-30; for GAPDH, 50-CCATCACCATCTTCCAGGAG-30
and 50-CCTGCTTCACCACCTTCTTG-30; for monocyte chemotactic
protein (MCP)-1, 50-ATAGCAGCCACCTTCATTCC-30 and 50-AGCTTC-
TTTGGGACACTTGC-30; for matrix metalloproteinase (MMP)-1, 50-
CTGCTTACGAATTTGCCGACAGA-30 and 50-GTTCTAGGGAAGCCAAA-
GGAGCTG-30; for MMP3, 50-AGCAAGGACCTCGTTTTCATT-30 and 50-
GTCAATCCCTGGAAAGTCTTCA-30. The PCR products were separated
using 1% agarose gel electrophoresis and visualized using ethidium
bromide staining.2.7. Western blot analysis
For Western blot analysis, cells were lysed with modiﬁed radio
immunoprecipitation assay (RIPA) buffer, including 50mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid
(EDTA), 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM DTT, 10
mMNaF,1 mM phenylmethanesulfonyl ﬂuoride (PMSF), aprotinin 1
mg/mL, leupeptin 1 mg/mL, and 1mMNa3VO4. Lysates were resolved
on a sodium dodecyl sulfate-containing 10% polyacrylamide gel,
transferred to polyvinylidene diﬂuoride nylon membrane, and
probed with speciﬁc antibodies at 4 C overnight. Speciﬁc bands
were detected using a horseradish peroxidase-conjugated antibody
and revealed using an enhanced chemiluminescence Western blot
system from Pierce (Rockford, IL, USA).2.8. Immunoprecipitation
U373MGcellswerewashedwith phosphate buffered saline (PBS).
LysatewaspreparedusingmodiﬁedRIPAbuffer. The supernatantwas
added with anti-CEBPD antibody at 4 C for 1 hour. Protein-A/G
agarose beads were added to the lysate, and the mixture was incu-
bated during shaking at 4 C for 1 hour. The beads were collected
using centrifugation and washed 3 times with modiﬁed RIPA buffer.
Proteins binding to the beads were eluted by adding 2X electropho-
resis sample buffer and followed byWestern blot analysis.2.9. Cell migration assays
For thewound-healing assay, BV-2 cells (5105)were cultured in
3.5-cm dishes and wounded with a sterile plastic tip, producing
scars, then incubated with different conditioned medium. Cell
migration into the open space was monitored using microscopy.
Photomicrographs were taken immediately and at 6 and 12 hours
after wounding. Relative migration activity of cells was analyzed
using WimScratch software (Wimasis, Munich, Germany). For
transwell migration, transwell ﬁlters (with 8-mm pore size; Corning
Costar, Bodenheim, Germany) containing BV-2 cells (105) were put
into a 24-well plate. Cells were allowed to migrate into the lower
chamber containing 300 mL conditioned medium for 3 hours and
then transwell insertswere removed for analysis. Cells remaining on
theupper surfaceof the insertwere carefullyaspirated, leaving those
that hadmigrated to the surface underneath in place. The insert was
then transferred to a clean well containing 225 mL of nonenzymatic
cell dissociation solution (Sigma) and incubated for 30minutes at 37
C. Cells were counted using phase-contrast microscopy.2.10. Lentiviral knockdown assay
Virus was produced from Phoenix cells by cotransfection of
the various small hairpin RNA (shRNA) expression vectors in
combination with pMD2.G and psPAX2. After determining the
viral infection efﬁciency, 10 multiplicity of infection of lentivirus
containing shb-galactosidase (shLacZ) or shCEBPD were used to
infect U373MG cells for 96 hours. In all lentiviral experiments,
medium containing uninfected viruses was removed before con-
ducting further assays. The shRNA sequences in lentiviral expression
vectors were: shb-galactosidase, 50-CCGGTGTTCGCATTATCCGAAC-
CATCTCGAGATGGTTCGGATAATGCGAACATTTTTG-30 and shCEBPD,
50-CCGGGCCGACCTCTTCAACAGCAATCTCGAGATTGCTGTTGAAGAG-
GTCGGCTTTTT-30. The lentiviral knockdown expression vectors
were obtained from the National RNAi Core Facility located at the
Genomic Research Center of Institute of Molecular Biology,
Academia Sinica (Taiwan).
2.11. Chromatin immunoprecipitation assay
The chromatin immunoprecipitation assay was carried out
essentially as described byWang et al. (2006). Brieﬂy, U373MG cells
were treated with 1% formaldehyde for 15 minutes. The cross-
linked chromatin was then prepared and sonicated to an average
size of 500 base pair. The DNA fragments were immunoprecipitated
with antibodies speciﬁc for CEBPD, phosphoCEBPDS167, or control
rabbit immunoglobulin G at 4 C overnight. After reversal of the
cross-linking, the immunoprecipitated chromatin was ampliﬁed
using primers related to the speciﬁc regions of the target genes’
genomic locus. The primers were: for MCP-1 genomic locus,
50-CTGGCATTTCTTCTGCAGCACTACATGC-30 and 50-AGCCAGGAAG-
GAGCTCTCAAGCTTTG-30; for MMP1 genomic locus, 50-CCACTGTT-
TACATGGCAGAGTGTGTCTC-30 and 50-CAGAAAGCCAGAGGCTGTC-
TGACTCATG-30; for MMP3 genomic locus, 50-GCTCCAGTTTT-
CTCCTCTACCAAGAC-30 and 50-GCTTTCATCCAAATGGCAGCAGGAC-
30. The ampliﬁed DNA products were resolved using agarose gel
electrophoresis and conﬁrmed using sequencing.
2.12. Immunoﬂuorescence analysis
Brain tissue dissections were postﬁxed in 4% buffered para-
formaldehyde for 24e36 hours, cryoprotected, sectioned at 10 mm
on a freezing microtome, and stored at 20 C in 33% glycerin, 33%
glycerol, and 33% phosphate buffer (pH 7.4) solutions. After per-
meabilizing with 0.4% Triton X-100 and blocking in 3% bovine
serum albumin, the slices were incubated overnight in ﬁrst anti-
body. After 3 washes in 0.2% Triton X-100/PBS, slices were incu-
bated with secondary antibody for 1 hour at room temperature.
Slices were thoroughly washed in 0.2% Triton X-100/PBS, counter-
stained and mounted on glass slides with ProLong Gold antifade
reagent with 40,6-diamidino-2-phenylindole (Invitrogen) for
immunoﬂuorescence microscopy analysis.
3. Results
3.1. CEBPD is highly expressed in the astrocytes of AppTg mice and
inﬂuences the activation of microglia
Elevated CEBPD expression has been found in astrocytes of AD
patients (Li et al., 2004). Although the level of mouse CEBPD
(Cebpd) is increased in the brain of AppTg mice (Ko et al., 2012), the
speciﬁcity of cells expressing Cebpd in these mice remains unclear.
Similar to AD patients, an immunoﬂuorescence assay showed that
the activation of Cebpd was mainly observed in the astrocytes of
AppTg mice (Fig. 1A). To further clarify the biological function of
050
100
AppTg AppTg/
Cebpd-/-
G
FA
P 
im
m
u
n
os
ig
na
l i
n
te
n
sit
y 
(%
)
AppTg/
Cebpd-/-
0
50
100
AppTg
Ib
a
1 
im
m
u
n
os
ig
na
l i
n
te
n
sit
y 
(%
)
A
B
C
D
Fig. 1. CCAAT/enhancer-binding protein delta (CEBPD) plays a functional role in the activation of astrocytes and microglia/macrophages in AppTg mice. (A) CEBPD is highly expressed
in the astrocytes of AppTg mice. Sagittal sections of brain cortex were prepared from AppTg mice and subjected to immunoﬂuorescence with anti-beamyloid, -GFAP, -Iba1, or -mouse
CEBPD (Cebpd) antibodies. (B) and (C) The numbers of activated astrocytes and microglia are attenuated in areas surrounding amyloid-b (Ab) plaques in AppTg/Cebpd/ mice.
Sagittal sections of brain cortex were prepared from AppTg or AppTg/Cebpd/ mice and subjected to immunoﬂuorescence with anti-Ab, -GFAP, or -Iba1 antibodies, respectively. (D)
Statistical analysis of GFAP or Iba1 immunoﬂuorescent staining intensity in brain slices of AppTg or AppTg/Cebpd/ mice using TissueQuest 4.0 image software (* p < 0.05, *** p <
0.001, Student t test). Abbreviations: GFAP, glial ﬁbrillary acidic protein; Iba1, induction of brown adipocytes 1.
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deﬁcient (Cebpd/) mice. We found that the number of activated
astrocytes was attenuated in the areas surrounding amyloid-b (Ab)
plaques in AppTg/Cebpd/ mice (Fig. 1B, lower panel) compared
with AppTg mice (Fig. 1B, upper panel) according to GFAP staining.
Moreover, the microglia activation was also decreased in in AppTg/
Cebpd/ mice (Fig. 1C, lower panel) compared with AppTg mice
(Fig. 1C, upper panel) according to Iba1 staining. The GFAP and Iba1
immunoﬂuorescent staining intensity was quantitated in brain
slices of AppTg or AppTg/Cebpd/ mice (Fig. 1D). These results
implied that astrocytic CEBPD might contribute to microglia acti-
vation and migration. In addition, the loss of Cebpd in AppTg mice
showed a signiﬁcant attenuation in the GFAP signal, suggesting that
Cebpd could also play an important role in astrogliosis of AD
pathogenesis.3.2. Proinﬂammatory cytokines can induce CEBPD phosphorylation
in astrocytes
We have reported that IL-1b and TNF-a can induce CEBPD gene
expression (Ko et al., 2012), though the speciﬁc mechanism of ac-
tion remains unknown. In addition, a mobility shift pattern was
observed after 3 hours of IL-1b and TNF-a exposure (Fig. 2A). To
determine whether this mobility shift pattern results from a
modiﬁcation of protein phosphorylation, we pretreated cell lysates
with calf intestinal alkaline phosphatase and conducted a Western
blot analysis. An attenuated mobility shift pattern suggests that IL-Fig. 2. Proinﬂammatory cytokines induce CCAAT/enhancer-binding protein delta
(CEBPD) phosphorylation in astrocytes. (A) U373MG cells were starved for 6 hours and
then restimulated with 5 ng/mL interleukin (IL)-1b or 20 ng/mL tumor necrosis factor
(TNF)-a respectively. At the indicated time points, cell lysates were harvested for
Western blot analysis with anti-CEBPD or -GAPDH antibodies. (B) Cell lysates were
treated with alkaline phosphatase (CIP) and incubated at 37 C. The samples were then
analyzed using Western blot with anti-CEBPD or -COXe1 antibodies. Abbreviations:
COX, cyclooxygenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.1b and TNF-a induce the phosphorylation of CEBPD in astrocytes
(Fig. 2B; compare lane 2 with 3 and lane 5 with 6).
The activation of GSK3b andMAPKp38 is altered after TNF-a and
IL-1b exposure in astrocytes (Rojo et al., 2008). We tested the effect
of GSK3b and MAPKp38 on the expression of CEBPD using LiCl, a
GSK3b inhibitor, and SB203580, a MAPKp38 inhibitor, respectively.
As shown in Fig. 3A, LiCl, but not SB203580, speciﬁcally inhibited
the phosphorylation of CEBPD induced by IL-1b or TNF-a (Fig. 3A
and Supplementary Fig. 1). This result suggests that CEBPD is a
GSK3b substrate mediated by IL-1b and TNF-a in astrocytes. To
identify the GSK3b-targeted Ser/Thr residues on the CEBPD protein,
various recombinant His/CEBPD proteins were produced for in vitro
kinase assay (Fig. 3B). The mutations of CEBPD/S167A and CEBPD/
T171A showed an attenuated GSK3b kinase effect (Fig. 3C). To
investigate the in vivo phosphorylation of CEBPDS167 and
CEBPDT171 in astrocytes, 2 antibodies that speciﬁcally recognize
CEBPDS167 and CEBPDT171 were generated. After using Western
blot analysis to assess these antibodies with in vitro GSK3b-phos-
phorylated His/CEBPD proteins (Supplementary Fig. 2), we exam-
ined the phosphorylation of CEBPD in astrocytes treated with IL-1b.
Western blot and immunoprecipitation analysis showed that
phosphorylated CEBPDS167 is detectable after IL-1b treatment
(Fig. 4). However, phosphorylated CEBPDT171 showed a consistent
phosphorylation pattern, suggesting that residue Ter171 is a
constitutive phosphorylation site; thus, CEBPD normally exists as a
hypophosphorylated protein in astrocytes.3.3. GSK3b-mediated phosphorylation of CEBPD at Ser167
contributes to the migration and chemoattractant detection of
microglia/macrophages
We sought to determine whether phosphorylated CEBPDS167
and CEBPDT171 in astrocytes play a functional role in the migration
and activation of microglia/macrophages, so we generated 2 other
zinc-induced stable clones of CEBPD, S167A and T171A, in astro-
cytes (Fig. 5A). First, we assessed changes in the conditional
medium collected from IL-1betreated astrocytes with or without
LiCl treatment. Three types of macrophages, BV-2 microglia, THP-1
macrophages (differentiated using phorbol-12-myristate-13-
acetate [PMA]) and primary bone marrow derived macrophage
(differentiated by macrophage colony-stimulating factor [M-CSF])
were used to assess the regulation of astrocytes. In awound-healing
assay, the conditional medium from LiCl-treated U373MG cells
inhibited IL-1beinduced mobility of BV-2 microglia (Fig. 5B). The
conditional medium from CEBPD-overexpressed U373MG cells
promoted the mobility of BV-2 microglia and primary macro-
phages; however, this phenomenon was attenuated in BV-2
microglia and primary macrophages cultured with conditional
medium from CEBPDS167A- or CEBPDT171A-overexpressed
U373MG cells (Fig. 5D and Supplementary Fig. 3A). These results
suggest that GSK3-mediated phosphorylation of CEBPD is impor-
tant in the migration of microglia/macrophages. We next tested
whether astrocytic CEBPD affects the chemoattraction of microglia/
macrophages. Using a transwell assay, we determined that the
chemoattraction of BV-2 microglia was increased when cultured
with conditioned medium from IL-1b-treated U373MG cells
(Fig. 5C). Importantly, the conditional medium from U373MG cells
overexpressing CEBPDS167A or CEBPDT171A showed an attenuated
effect in BV-2 microglia and THP-1 macrophages when compared
with the conditioned medium from U373MG cells overexpressing
CEBPD (Fig. 5E and Supplementary Fig. 3B). These data indicate that
certain secretory factors involved in promoting cell migration were
attenuated in the conditioned medium of CEBPDS167A and
CEBPDT171A-overexpressed U373MG cells.
Fig. 3. Glycogen synthase kinase (GSK)-3b mediates interleukin (IL)-1beinduced CCAAT/enhancer-binding protein delta (CEBPD) phosphorylation in U373MG cells. (A) GSK3b, but
not MAPKp38, mediates IL-1beinduced CEBPD phosphorylation. U373MG cells were pretreated with the GSK3b inhibitor LiCl or the MAPKp38 inhibitor SB203580 before IL-1b
treatment. At the time points indicated, cell lysates were harvested for Western blot analysis with speciﬁc antibodies. (B) The putative phosphorylation sites of GSK3b, MAPKp38,
and CDK5 on CEBPD are represented by numbers. (C) The residues of Ser167 and Thr171 on CEBPD are the phosphorylation-conjugating sites of GSK3b. The in vitro kinase assay was
performed using various kinase incubations with various recombinant CEBPD proteins. The in vitro casein kinase I (CKI) kinase assay served as a positive control because CEBPD is a
known CKI substrate. Abbreviations: CDK, cyclin-dependent kinase; MAPK, mitogen-activated protein kinase.
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that control cell migration and chemoattraction, we assessed the
global proﬁling of CEBPD-responsive genes in U373MG cells (Ko
et al., 2012). Several factors involved in chemoattraction and cell
migration, including MCP-1, MMP1 and MMP3, were identiﬁed.
Next, we examined whether these genes were regulated by IL-1b
and CEBPD in astrocytes. After IL-1b exposure, the knockdown of
CEBPD attenuated IL-1b-induced MCP-1, MMP1, and MMP3transcripts (Fig. 6A). A reporter assay was conducted using the
cotransfection of CEBPD expression vectors with various reporters.
This assay showed that the phosphorylation mutations
CEBPDS167A and CEBPDT171A blocked the CEBPD-induced re-
porter activity (Fig. 6B). Finally, an in vivo DNA binding assay was
conducted to determine whether CEBPD binds to the promoter
region of the identiﬁed genes. As shown in Fig. 6C, IL-b induced
the binding of CEBPD to the promoter regions ofMCP-1,MMP1, and
Fig. 4. Glycogen synthase kinase (GSK)-3b mediates interleukin (IL)-1beinduced CCAAT/enhancer-binding protein delta (CEBPD) Ser167 phosphorylation in U373MG cells. (A) LiCl
inhibits IL-1beinduced CEBPD Ser167 phosphorylation. U373MG cells were pretreated with LiCl, a GSK3b inhibitor, before IL-1b treatment. At the time points indicated, cell lysates
were harvested for Western blot analysis with speciﬁc antibodies, including anti-CEBPD, -CEBPDS167 (pS167), -CEBPDT171 (pT171), -GSK3b, or -aetubulin. (B) GSK3b phosphor-
ylates CEBPD Ser167 after IL-1b stimulation. U373MG cells were pretreated with LiCl before IL-1b treatment. Cells underwent immunoprecipitation with the CEBPD antibody. The
immunocomplex was probed with a pS167 antibody for Western blot analysis.
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Ser167 produced a similar effect.
4. Discussion
In postmortem AD tissue, activated astrocytes were closely asso-
ciated with amyloid plaques in the molecular layer of the cerebral
cortex. It is known that astrocytes can be activated by Ab, which in-
dicates a correlationbetween this protein andsubsequent alterations
in astrocyte function. Activation of CEBPD is observed in many in-
ﬂammatory diseases, indicating that it is a common factor in in-
ﬂammatory environments and might play a critical role in the
pathogenesis of neuroinﬂammation. In this study, we found that
Cebpd was highly expressed in activated astrocytes of AppTg mice.
These data are similar to a previous report in human patient speci-
mens (Li et al., 2004). Moreover, the loss of Cebpd in AppTg mice
produced signiﬁcant attenuationofGFAPand Iba1signals, suggesting
that Cebpd plays an important role in astrocyte and microglial acti-
vation. However, it remains to be examined whether the loss of
Cebpd alters Ab plaque deposition. After inducing CEBPD expression
with IL-1b in astrocytes, we identiﬁed that GSK3b phosphorylates
Ser167 of CEBPD; furthermore, the phosphorylation of astrocytic
CEBPD contributes to the activation and migration of microglia/
macrophages. This novelﬁnding highlights the importance of CEBPD
in activated astrocytes and neuroinﬂammatory diseases.
Different from neurons, astrocytic CEBPD is phosphorylated by
GSK3b and consequently activates the expression of MCP-1, MMP3,
and MMP1 by binding to their promoter regions. Previously, we
demonstrated that epidermal growth factor can induce CEBPD
transcriptional activation through the MAPKp38/cAMP response
element-binding protein pathway in A431 cells (Wang et al., 2005).
CEBPDwas suggested to be aMAPKp38 substrate and was shown to
interact with MAPKp38 using in vitro kinase and binding assays,
respectively (Svotelis et al., 2005). Our in vitro kinase assay showed
that recombinant MAPKp38 protein phosphorylated CEBPD but not
CEBPDS167A and CEBPDT171A mutations (Supplementary Fig. 4A).
However, treatment with the GSK3b inhibitor LiCl, but not the
MAPKp38 inhibitor SB203580, shifted the pattern of IL-1beinduced
CEBPD phosphorylation in U373MG cells (Fig. 3A; compare lane 3
with 4). Interestingly, SB203580 treatment showed a coincident
result of attenuating CEBPD protein expression as in A431 cells
(Wang et al., 2005). These results suggest thatMAPKp38 plays a role
in regulating CEBPD transcription, but not the posttranslational
modiﬁcation of CEBPD, in a cell type-dependent manner.In addition to the IL-1be and TNF-aeinduced phosphorylation of
CEBPDS167 in astrocytes, our preliminary results show that EGFalso
induces phosphorylation of CEBPD at the sameposition inA431 cells
(Supplementary Fig. 5A; compare lane 3 with 7). Furthermore,
various gel-retarded patterns were observed in A431 cells
responding to EGF treatment, similar to the phenomenon of hypo-
and hyperphosphorylation of retinoblastoma tumor suppressor
protein (Supplementary Fig. 5B). Brieﬂy, the EGF-induced phos-
phorylation of CEBPD (Supplementary Fig. 5B; compare lane 3 with
lane 1) was attenuated when the lysate was treated with a phos-
phatase (Supplementary Fig. 5B; compare lane 4with lane 3). CEBPD
was observed at a lower position in phosphatase-treated lysates
without EGF treatment (Supplementary Fig. 5B; compare lane2with
lane 1). These observations suggest that CEBPD is constitutively
phosphorylated in the absence of EGF and rapidly hyper-
phosphorylated when stimulated by EGF. Although our current re-
sults suggest that the phosphorylation of CEBPDS167 is important
for regulatingMCP-1,MMP1, andMMP3, and consequentlyaffects the
recruitment of microglia/macrophages, we cannot rule out that
other kinases, such as casein kinase I, regulate CEBPD at other resi-
dues in response to IL-1b and TNF-a in astrocytes.
In mammals, GSK3a and b are widely expressed at the RNA and
protein levels, although some tissues show preferential expression
of one of the isoforms. GSK3a and b are expressed in astrocytes.
GSK3b has been suggested to play a more important role than
GSK3a in the nervous system (Hur and Zhou, 2010). Although
GSK3b was proven to regulate pathogenic mechanisms of AD and
Parkinson’s disease (Bhat and Budd, 2002; Nagao and Hayashi,
2009), our current evidence cannot rule out the possibility that
CEBPDS167 is a GSK3a substrate. However, additional experiments
are needed to clarify the involvement of GSK3a because LiCl inhibits
GSK3a and b activity. Some GSK3 substrates do not require a spe-
ciﬁc sequence, but rather phosphorylation by a priming kinase on a
Ser or Thr residue phosphorylated at the fourth amino acid. This
priming facilitates the phosphorylation of a Ser or Thr residue on
the ﬁrst amino acid by GSK3. Although this priming phosphoryla-
tion has been suggested to be a feature on GSK3b-phosphorylated
substrates (Cohen and Frame, 2001; Jope and Johnson, 2004),
increased evidence shows that GSK3b can phosphorylate substrates
in a priming-independent manner (Cho and Johnson, 2003; Doble
and Woodgett, 2003). In this study, GSK3b can phosphorylate
Ser167 and Thr171 of CEBPD in an in vitro kinase assay. After the
treatment of IL-1b, GSK3b activity is attenuated between 0 and 3
hours (Fig. 3A). This activity matches the phosphorylation state of
Fig. 5. Phosphorylation of CCAAT/enhancer-binding protein delta (CEBPD) in astrocytes attenuates the migration of microglia/macrophages. (A) U373MG cells stably transfected
with a zinc-inducible CEBPD expression vector were exposed to 100 mM ZnSO4 and wild type or mutant HA-tagged CEBPD protein expression was analyzed using Western blot. (B)
and (D) Wound-healing migration assays were performed with BV-2 cells. Conditional medium from drug treatments or different CEBPD-overexpressed stable clones in U373MG
cells exposed to interleukin (IL)-1b was added to the BV-2 cells. Photomicrographs were taken at the indicated time points. One representative experiment is shown and similar
results were obtained in 3 independent cultures. (C) and (E) An in vitro chemotaxis assay with 8-mm transwell ﬁlter cultures was completed. Conditional medium from drug
treatments or different CEBPD-overexpressed stable clones in U373MG cells after IL-1b treatment were put in a 24-well plate, and BV-2 cells were added to the transwell inserts.
Transwell inserts were removed after 3 hours, and cells crossing the insert membrane were counted. Data represent the mean  standard error of the mean of 3 independent cell
cultures analyzed in triplicate wells (* p < 0.05, ** p < 0.01, Student t test). Abbreviations: C, control; CD, CEBPD wild type; S167A, CEBPD S167A; T171A, CEBPD T171A; HA,
hemagglutinin.
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whether the phosphorylation of Thr171 is an essential prime po-
sition for the further phosphorylation of Ser167, whether the
phosphorylation of Ser167 and Thr171 by GSK3b can be indepen-
dent, and whether CEBPDT171 is phosphorylated by otherconstitutively activated kinases, such as CKI. These issues need to be
further investigated to determine their effects on the communica-
tion of microglia/macrophages and astrocytes.
MCP-1, a predominant chemoattractant, causes the migration
and activation of microglia and macrophages (McManus et al.,
Fig. 6. CCAAT/enhancer-binding protein delta (CEBPD) transcriptional activity is enhanced after interleukin (IL)-1beinduced phosphorylation. (A) Loss of CEBPD attenuates IL-
1beinduced MCP1, MMP1, and MMP3 transcripts. Reverse transcription polymerase chain reaction assays were performed with total RNA harvested from U373MG cells transfected
with shb-galactosidase (shLacZ) or shCEBPD after IL-1b treatment. (B) Inhibition of CEBPD phosphorylation decreases its transcriptional activity. The reporter vector carrying the
MMP1,MMP3, orMCP1 promoter was cotransfected with the indicated expression vectors in U373MG cells. After 12 hours, the cells were treated with IL-1b for 3 hours and then the
cell lysates were harvested for a luciferase assay (* p < 0.05, ** p < 0.01, *** p < 0.001, Student t test). (C) Phosphorylated CEBPD bound to its downstream target genes after IL-1b
treatment. Chromatin from U373MG cells was immunoprecipitated (IP) with speciﬁc antibodies, including a control immunoglobulin G (IgG), CEBPD, or pCEBPD (S167) after 3 hours
of IL-1b treatment. The precipitated DNA was ampliﬁed using speciﬁc primers for the MCP1, MMP1, or MMP3 promoter regions. Abbreviation: sh, small hairpin.
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neurotoxic at the sites of inﬂammation (Kaul et al., 2001; Persidsky
and Gendelman, 2003). MCP-1 is primarily secreted by monocytes,
macrophages, and dendritic cells. Previous reports showed that
MCP-1 can be produced after Ab treatment in a human U373MG
astrocyte cell line (Prat et al., 2000) and might be linked to the
maturation or degradation of senile plaques (Hurwitz et al., 1995;
Ishizuka et al., 1997; Madrigal et al., 2009). Here, we demon-
strated that a novel IL-1b/GSK3b/pCEBPDS167 pathway activates
MCP-1 expression in astrocytes. These ﬁndings also provide evi-
dence to explain why the conditioned medium harvested from
U373MG cells expressing CEBPD promoted the migration and
activation of microglia/macrophages. MMPs comprise a family of
proteolytic enzymes that are involved in the remodeling of the
extracellular matrix in many tissues. They have been implicated in
the degradation of vascular basement membranes thereby facili-
tating leukocyte migration into inﬂammatory sites. A growing
amount of evidence suggests that MMPs might play an important
role in the pathogenesis of AD (Gottschall and Deb, 1996). Microglia
and astrocytes have been shown to synthesize and secrete a wide
range of MMP’s, including MMP1, MMP2, and MMP3, afteractivation by Ab peptide treatment in vitro. MMP1, MMP3, and
matrix metallopeptidase 9 are elevated in AD patients; however,
the underlying mechanism for this ﬁnding is unknown (Leake et al.,
2000; Lorenzl et al., 2003). In this study, we found that MMP1 and
MMP3 were elevated through a CEBPD-dependent pathway after
IL-1b treatment in astrocytes.
In addition to MCP-1, as already mentioned, CEBPD was sug-
gested to be involved in the transcriptional activation of IL-6, IL-1b,
and TNF-a genes in various cell types. In astrocytes, we show that
IL-1b induces the binding of CEBPD to promoters of its downstream
genes. It implies a potent positive feedback regulation between
CEBPD and proinﬂammatory cytokines IL-6, IL-1b, and TNF-a in
astrocytes. However, the detailed mechanism of CEBPD-mediated
gene regulation of these inﬂammatory cytokines remains to be
investigated. Sixmembers have been identiﬁed inmammalian cells,
including CEBP alpha, CEBP beta, CEBPD, CEBP epsilon, CEBP
gamma, and CEBP zeta. All CEBPs consist of a canonical basic
domain and a C-terminal leucine zipper domain. The basic region
binds to speciﬁc CCAAT motifs located in CEBP’s targeted gene
promoter, whereas the leucine zipper domain is responsible for
heterodimer/homodimer formation between various CEBP
C.-Y. Ko et al. / Neurobiology of Aging 35 (2014) 24e34 33members (Ramji and Foka, 2002). Actually, CEBP beta is also
induced by IL-1b through the MAPKp38 pathway in astrocytes
(Maranto et al., 2011). However, the details and consequences
related to interactions of CEBPD and other C/EBP family members in
astrocytes still needs to be further investigated.
In response to damage, astrocytes can be activated. In addition,
they are resistant to death receptor-induced apoptosis, which in-
dicates that they are well equipped to survive inﬂammatory insults.
The activation of astrocytes can be characterized by several fea-
tures. First, the most commonly usedmarker of activated astrocytes
is their upregulation of intermediate ﬁlaments (GFAP, vimentin, and
to some extent, nestin) coincident with cellular hypertrophy and
cell proliferation. Second, activated astrocytes are likely to increase
their expression of cytokines, chemokines, and extracellular matrix
components (Sofroniew, 2009). Astrogliosis involves changes in the
molecular expression and morphology of astrocytes. In severe
cases, astrogliosis can lead to scar formation. Reactive astrogliosis
consists of a spectrum of changes that occur in response to all forms
and severities of CNS injury and diseases (Correa-Cerro and
Mandell, 2007; Maragakis and Rothstein, 2006; Pekny and
Nilsson, 2005). Scarring astrocytes are considered to be a major
impediment to the regeneration of damaged axons and reactive
gliosis is regarded as being detrimental to nervous tissue repair and
functional restoration (Kiyota et al., 2009; Potts and Leech, 2005;
Rodriguez et al., 2009). Therefore, molecular dissection of reactive
astrogliosis is imperative for the development of novel therapeutic
strategies. In our preliminary results, we found that GFAP was
induced by CEBPD-overexpressing astrocytes (Ju-Ming Wang, un-
published results). The role of CEBPD in reactive astrogliosis should
be further investigated.
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